. 2018 Feb 23;10(2):255. doi: 10.3390/nu10020255

Table 4.

Isokinetic measures for the dominant leg at baseline, and changes across a supplementation period in both groups.

Variables	Group	Baseline Mean ± SD	Observed Change Mean ± SD	Adjusted Change ^a Mean ± SD	Adjusted Effect ^b
Variables	Group	Baseline Mean ± SD	Observed Change Mean ± SD	Adjusted Change ^a Mean ± SD	Mean; CL	Inference
TW extension (J/kg)	placebo	76 ± 15	7.4 ± 26%	5.7 ± 8.3%	5.6%; ±7.1%	trivial *
TW extension (J/kg)	l-carnitine	78 ± 11	11 ± 13%	12 ± 9.5%	5.6%; ±7.1%	trivial *
TW flexion (J/kg)	placebo	43 ± 17	9.4 ± 40%	13 ± 13%	−2.9%; ±13%	trivial *
TW flexion (J/kg)	l-carnitine	36 ± 9	14 ± 34%	9.7 ± 23%	−2.9%; ±13%	trivial *
APT extension (Nm/kg)	placebo	12.0 ± 2.6	4.7 ± 20%	1.9 ± 9.7%	3.0%; ±9.0%	unclear
APT extension (Nm/kg)	l-carnitine	12.8 ± 2.3	2.7 ± 18%	5.0 ± 13%	3.0%; ±9.0%	unclear
APT flexion (Nm/kg)	placebo	6.8 ± 2.6	4.9 ± 26%	7.0 ± 7.8%	−4.2%; ±9.0%	trivial *
APT flexion (Nm/kg)	l-carnitine	5.9 ± 1.1	5.0 ± 22%	2.6 ± 16%	−4.2%; ±9.0%	trivial *
AP extension (W/kg)	placebo	8.3 ± 2.0	6.3 ± 25%	3.9 ± 6.2%	1.4%; ±6.8%	trivial ^†
AP extension (W/kg)	l-carnitine	8.6 ± 1.4	3.3 ± 18%	5.4 ± 11%	1.4%; ±6.8%	trivial ^†
AP flexion (W/kg)	placebo	4.4 ± 1.7	10 ± 40%	14 ± 12%	−7.1%; ±9.7%	trivial ^†
AP flexion (W/kg)	l-carnitine	3.9 ± 1.4	12 ± 83%	5.8 ± 17%	−7.1%; ±9.7%	trivial ^†

CL, 90% confidence limit; * possible, ^† likely. ^a Adjusted to the overall mean of both groups at baseline. ^b Adjusted mean change in the l-carnitine group minus the adjusted mean change in the placebo group. TW: total work; APT: average peak torque; AP: average power.